Skip to content
Biotechnology

Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for better bone repair

Monash University 2 mins read

Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates and screws typically used to hold fractured bones together. 

Surgeons routinely use stainless steel or titanium, which stay in the body forever, can cause discomfort and may require follow-up surgeries. A new zinc alloy, designed by Monash biomedical engineers, could solve these problems by being mechanically strong but gentle enough to degrade safely over time while supporting optimal healing.

A study published today in Nature shows the research team’s innovative approach to making the zinc alloy as strong as permanent steel implants and more durable than other biodegradable options like magnesium-based implants.

Lead researcher, Professor Jian-feng Nie, from the Department of Materials Science and Engineering, said the innovative material had the potential to transform orthopaedic care by reducing complications, minimising the need for additional surgeries, and offering a sustainable alternative to permanent metallic implants.

“Our zinc alloy material could revolutionise orthopaedic care – opening the door to safer, smaller implants that not only enhance patient comfort but also promote better healing outcomes by minimising disruption to surrounding tissues,” Professor Nie said.

“An implant that never disappears will always be a risk to the patient. On the other hand, one that degrades too fast won’t allow adequate time for the bones to heal. With our zinc alloy material, we can achieve the optimal balance between strength and controlled degradation of the implant to promote better healing.”

The research shows that by engineering the size and orientation of the material’s grains, the zinc alloy can bend and adapt in unique ways to accommodate the shapes of its neighbouring tissues. 

“This made it not only stronger but more flexible, offering a game-changing alternative for orthopaedics,” Professor Nie said.

The research is paving the way for a new start-up to be launched out of Monash University with a focus on developing next-generation biodegradable implants.

https://doi.org/10.1038/s41586-024-08415-8

-ENDS-

MEDIA ENQUIRIES:

Courtney Karayannis, Media and Communications Manager

Monash University

T: +61 408 508 454 or Courtney.Karayannis@monash.edu 



Monash University Media | +613 9903 4840 | media@monash.edu 

Visit Monash Lens for expert insights and commentary

 

Media

More from this category

  • Biotechnology, Business Company News
  • 26/03/2025
  • 10:11
Jane Morgan Management

LTR Pharma Multi-Market Strategy and Regulatory Update

26 March 2025 – LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to provide an update to the Company’s commercial and regulatory processes, highlighting the strong progress that has been made toward the global commercialisation and approvals for its innovative intranasal erectile dysfunction (ED) treatment, SPONTAN®. Highlights Successful FDA pre-IND meeting has outlined a clear approval pathway for SPONTAN® in the United States. Introduction of new product, Roxus®, a vardenafil-based nasal spray targeting the personalised healthcare market via US compounding pharmacy channel. Recognition at USANZ conference – SPONTAN® has been shown to deliver 470% faster absorption than…

  • Contains:
  • Biotechnology, Business Company News
  • 19/03/2025
  • 11:22
Jane Morgan Management

BlinkLab Expands Autism Diagnostics to Adults – New Collaboration with VU Amsterdam and NAR

19 March 2025 | BlinkLab Limited (ASX: BB1) (“BlinkLab” or the “Company”) is pleased to announce its newest partnership with Vrije Universiteit Amsterdam (VU Amsterdam) and the Netherlands Autism Register (NAR) in order to advance research on autism detection in adults. This study will complement BlinkLab’s ongoing FDA-registration trial for the diagnossis of autism in children, and is a significant step in expanding clinical applications for the AI-powered diagnostic tool that BlinkLab has developed. Highlights New study evaluating BlinkLab's autism detection smartphone app in adults, including adult-diagnosed autism. A focus on underdiagnosed populations, particularly women with autism, whom have historically…

  • Contains:
  • Biotechnology
  • 18/03/2025
  • 08:55
OncoSil Medical Limited (ASX:OSL)

OncoSil Medical (ASX:OSL) appoints Ms Shelley Steyn as Chief Financial Officer

Sydney, Australia – 18 March 2025: The Board of pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce the appointment of Ms Shelley Steyn as Chief Financial Officer (“CFO”) with effect from 5 May 2025. The appointment reflects OncoSil’s ongoing commitment to strengthening its leadership. As OncoSil enters a critical phase of development Ms Steyn’s appointment at Chief Financial Officer will bolster the Company’s ability to drive the Company’s strategic priorities. Ms Steyn brings to OncoSil extensive experience with more than 17 years in senior accounting, commercial and financial analysis and audit…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.